Journal article

International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA)

J Savige, D Gillis, E Benson, D Davies, V Esnault, RJ Falk, EC Hagen, D Jayne, JC Jennette, B Paspaliaris, W Pollock, C Pusey, COS Savage, R Silvestrini, F van der Woude, J Wieslander, A Wiik

American Journal of Clinical Pathology | AMER SOC CLIN PATHOLOGISTS | Published : 1999


Antineutrophil cytoplasmic antibody (ANCA) tests are used to diagnose and monitor inflammatory activity in the primary systemic small vessel vasculitides. ANCA is best demonstrated in these diseases by using a combination of indirect immunofluorescence (IIF) of normal peripheral blood neutrophils and enzyme-linked immunosorbent assays (ELISAs) that detect ANCA specific for proteinase 3 (PR3) or myeloperoxidase (MPO). For ANCA testing in "new" patients, IIF must be performed on all serum samples. Serum samples containing ANCA, any other cytoplasmic fluorescence, or an antinuclear antibody (ANA) that results in homogeneous or peripheral nuclear fluorescence then should be tested in ELISAs for ..

View full abstract